Meningitis
Also known as: Spinal meningitis, Fungus, Fungal, Fungii, Mold
Methodology & AI Transparency ⓘ
Meningitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Meningitis is inflammation of the thin tissue that surrounds the brain and spinal cord, called the meninges.
- 2 Real-world patient consensus: Diagnostic registry G03.9: Meningitis is managed within Infections & Antivirals (aka Spinal meningitis).
- 3 Typical cash cost range: Workup highlights for Meningitis (G03.9): antimicrobial stewardship (narrow-spectrum in Meningitis (G03.9: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Follow-up benchmark in Meningitis: maintaining Targeted PCR / in Meningitis (G03.9: Culture & Sensitivity) within Pathogen clearance / negative test (G03.9).
Ask our AI Specialists anything about Meningitis
What Is Meningitis?
Meningitis is inflammation of the thin tissue that surrounds the brain and spinal cord, called the meninges. There are several types of meningitis. The most common is viral meningitis. You get it when a virus enters the body through the nose or mouth and travels to the brain. Bacterial meningitis is rare but can be deadly. It usually starts with bacteria that cause a cold-like infection. It can cause stroke , hearing loss , and brain damage. It can also harm other organs. Pneumococcal infections and meningococcal infections are the most common causes of bacterial meningitis. Anyone can get meningitis, but it is more common in people with weak immune systems.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Meningitis (code G03.9) is localized inflammatory exudate [Meningitis G03.9], Cross-referenced with NIH MeSH (Meningitis), which Bacterial, Viral & Fungal Infections clinicians address while surveilling Targeted PCR / in Meningitis (G03.9: Culture & Sensitivity) (Pathogen clearance / negative test (G03.9)).
Common Symptoms & Clinical Signs
- • A sudden high fever
- • Nausea or vomiting
- • Presentation of Meningitis (G03.9): sore throat, productive in Meningitis (G03.9: cough, sinus/ear pain,)
- • Secondary Meningitis clinical sign: painful vesicular rash in Meningitis (G03.9: in a dermatomal)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Meningitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G03.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in Meningitis (G03.9: Culture & Sensitivity) | Pathogen clearance / negative test (G03.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Meningitis (G03.9: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (G03.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Meningitis (G03.9: Procalcitonin) | Resolution to baseline (G03.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Meningitis
Treatment selection for Meningitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Meningitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in: What a 218-Participant Study Found Neither noninferiority nor superiority of placebo was established in human immunodeficiency virus-negative LTA4H CC- and CT-genotype adults with tuberculous meningitis, and dexamethasone was safe. Nature medicine • 2026-03-15 • Phase III Randomized Trial | N = 218 | 88/100 | PMID 41540106 ↗ |
| New Insights on Long-acting cabotegravir how the body absorbs the medicine with and without oral: What a 278-Participant Study Found Findings are consistent between assigned-male-at-birth and assigned-female-at-birth populations. Antimicrobial agents and chemotherapy • 2024-06-05 • Phase III Randomized Trial | N = 278 | 87/100 | PMID 38709006 ↗ |
| New Insights on A randomised comparison of management strategies for drug-induced liver injury: What a 520-Participant Study Found DILI management strategies that increase transaminase drug-stopping thresholds (10X ULN), or stop pyrazinamide alone, appeared safe and reduced rifampicin/isoniazid interruptions vs. The Journal of infection • 2026-08-15 • Phase III Randomized Trial | N = 520 | 87/100 | PMID 42309188 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect staying on track Marginal structural models produced efficacy estimates (95% CIs) ranging from 48.8 (21.8, 66.4) (P = 0.0019) to 56.5% (32.8%, 71.9%) (P = 0.0002). AIDS and behavior • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39158801 ↗ |
| Can This Approach Help? Inside the Latest Research on High concordance in plasma and CSF HIV-1 drug resistance mutations despite high There was high concordance in HIV-1 drug resistance mutations in the CSF and plasma, suggesting intercompartmental mixing and possibly a lack of compartmentalization. The Journal of antimicrobial chemotherapy • 2022-12-23 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36322466 ↗ |
Meningitis Patient Community & “People Like Me” Threads
Filter Meningitis community threads and patient logs by age, biological sex, dosage, and treatment duration.